Back to News
Market Impact: 0.25
CAPR Stock Drop: Capricor Therapeutics Faces Securities Fraud Class Action Over Clinical Data; BFA Law Reminds Investors of September 28 Deadline
Source: globenewswire.com
Legal & LitigationHealthcare & BiotechCompany FundamentalsRegulation & Legislation
Capricor Therapeutics is facing a securities fraud class action over alleged clinical data issues, according to BFA Law. The firm also reminded investors of a September 28 deadline to participate in the action. The headline risk is higher uncertainty around clinical/regulatory credibility and potential litigation costs, which can weigh on the stock in the near term.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.55
Ticker Sentiment
CAPR-0.90
More News
- Indonesian stocks plunge to six-year low as MSCI downgrade fears mount
- China's CXMT sees shares drop over 6% as investors look past chipmaker's profit turnaround
- Australia’s Cleanaway agrees to $6.5 bln EQT buyout bid; shares surge
- India’s Finance Minister blames easy exits and excess liquidity for equity market's underperformance
- Daiichi Life Offers to Buy Remainder of Australia’s Challenger
- France's Macron vows to hold accountable those who 'sought to bring down the Republic'